PE20050286A1 - Formulacion de multiparticulas que comprenden oxicodona - Google Patents
Formulacion de multiparticulas que comprenden oxicodonaInfo
- Publication number
- PE20050286A1 PE20050286A1 PE2004000617A PE2004000617A PE20050286A1 PE 20050286 A1 PE20050286 A1 PE 20050286A1 PE 2004000617 A PE2004000617 A PE 2004000617A PE 2004000617 A PE2004000617 A PE 2004000617A PE 20050286 A1 PE20050286 A1 PE 20050286A1
- Authority
- PE
- Peru
- Prior art keywords
- oxycodone
- formulation
- water
- oxicodone
- multiparticles
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 abstract 3
- 229960002085 oxycodone Drugs 0.000 abstract 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229940049654 glyceryl behenate Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 229940071117 starch glycolate Drugs 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
- 238000010998 test method Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0315137A GB0315137D0 (en) | 2003-06-27 | 2003-06-27 | Multiparticulates |
| GB0403102A GB0403102D0 (en) | 2004-02-12 | 2004-02-12 | Multiparticulates |
| GB0413454A GB0413454D0 (en) | 2004-06-16 | 2004-06-16 | Multiparticulates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050286A1 true PE20050286A1 (es) | 2005-06-13 |
Family
ID=33556051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000617A PE20050286A1 (es) | 2003-06-27 | 2004-06-24 | Formulacion de multiparticulas que comprenden oxicodona |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1644002B1 (https=) |
| JP (2) | JP5348841B2 (https=) |
| KR (1) | KR101116518B1 (https=) |
| AR (1) | AR044935A1 (https=) |
| AT (1) | ATE453394T1 (https=) |
| AU (1) | AU2004251481B2 (https=) |
| BR (1) | BRPI0411901B1 (https=) |
| CA (1) | CA2530385C (https=) |
| CY (2) | CY1109917T1 (https=) |
| DE (1) | DE602004024888D1 (https=) |
| DK (2) | DK1889621T3 (https=) |
| EA (1) | EA013424B1 (https=) |
| ES (2) | ES2337468T3 (https=) |
| HR (2) | HRP20100127T1 (https=) |
| IL (1) | IL172730A (https=) |
| MX (1) | MXPA05013799A (https=) |
| MY (1) | MY176831A (https=) |
| NO (1) | NO20060443L (https=) |
| NZ (1) | NZ544181A (https=) |
| PE (1) | PE20050286A1 (https=) |
| PL (2) | PL1644002T3 (https=) |
| PT (2) | PT1644002E (https=) |
| SI (2) | SI1889621T1 (https=) |
| TW (1) | TWI357815B (https=) |
| WO (1) | WO2005000310A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| EP1041987B1 (en) | 1997-12-22 | 2006-04-19 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone |
| EP1387673B1 (en) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
| HUE032656T2 (en) | 2002-04-05 | 2017-10-30 | Euro Celtique Sa | Pharmaceutical composition containing oxicodone and naloxone |
| WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
| TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| GEP20105052B (en) * | 2005-01-28 | 2010-07-26 | Euro Celtique Sa | Alcohol resistant dosage forms |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP1991207A2 (en) * | 2006-01-21 | 2008-11-19 | Abbott GmbH & Co. KG | Dosage form and method for the delivery of drugs of abuse |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| CA2678367C (en) * | 2007-03-02 | 2014-07-08 | Farnam Companies, Inc. | Sustained release compositions using wax-like materials |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| RU2465916C2 (ru) * | 2007-10-19 | 2012-11-10 | Оцука Фармасьютикал Ко., Лтд. | Твердый фармацевтический препарат матричного типа |
| US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
| BRPI0913724B8 (pt) * | 2008-09-18 | 2021-05-25 | Purdue Pharma Lp | formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| SG174286A1 (en) | 2009-03-10 | 2011-10-28 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| JP2013519877A (ja) * | 2010-02-11 | 2013-05-30 | ハリー ライダー， | 測定された薬物濃度の正規化方法、及び薬物治療レジメンのノンコンプライアンスを検査するための方法 |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| AU2013285988A1 (en) | 2012-07-06 | 2015-02-12 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| JP2016525138A (ja) | 2013-07-23 | 2016-08-22 | ユーロ−セルティーク エス．エイ． | 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| AU660290B2 (en) * | 1990-08-09 | 1995-06-22 | Endocon, Inc. | Multiple drug delivery system |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| DE69530973T2 (de) * | 1994-02-16 | 2004-05-19 | Abbott Laboratories, Abbott Park | Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| CA2219995C (en) * | 1995-05-01 | 2004-04-13 | Sam Yang Co., Ltd. | Implantable bioresorbable membrane and method for the preparation thereof |
| SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
| WO1997045091A2 (en) * | 1996-05-31 | 1997-12-04 | Euro-Celtique, S.A. | Sustained release oxycodone formulations with no fed/fast effect |
| US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| FR2795326B1 (fr) * | 1999-06-28 | 2001-08-31 | Adir | Composition pharmaceutique solide thermoformable a liberation controlee |
| AU764453B2 (en) * | 1999-10-29 | 2003-08-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| EP2092936B1 (en) * | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| FR2818552B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine |
| WO2003094888A1 (en) * | 2002-05-07 | 2003-11-20 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| CN1741792A (zh) * | 2003-01-24 | 2006-03-01 | 控制递送系统有限公司 | 经眼部递送肾上腺素能剂的持续释放系统和方法 |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
-
2004
- 2004-06-18 TW TW093117618A patent/TWI357815B/zh not_active IP Right Cessation
- 2004-06-23 SI SI200432174T patent/SI1889621T1/sl unknown
- 2004-06-23 PL PL04743056T patent/PL1644002T3/pl unknown
- 2004-06-23 DK DK07013702.1T patent/DK1889621T3/da active
- 2004-06-23 PL PL07013702T patent/PL1889621T3/pl unknown
- 2004-06-23 CA CA2530385A patent/CA2530385C/en not_active Expired - Fee Related
- 2004-06-23 BR BRPI0411901-0A patent/BRPI0411901B1/pt not_active IP Right Cessation
- 2004-06-23 SI SI200431330T patent/SI1644002T1/sl unknown
- 2004-06-23 EP EP04743056A patent/EP1644002B1/en not_active Expired - Lifetime
- 2004-06-23 EP EP07013702.1A patent/EP1889621B1/en not_active Expired - Lifetime
- 2004-06-23 PT PT04743056T patent/PT1644002E/pt unknown
- 2004-06-23 MX MXPA05013799A patent/MXPA05013799A/es active IP Right Grant
- 2004-06-23 DE DE602004024888T patent/DE602004024888D1/de not_active Expired - Lifetime
- 2004-06-23 ES ES04743056T patent/ES2337468T3/es not_active Expired - Lifetime
- 2004-06-23 AT AT04743056T patent/ATE453394T1/de active
- 2004-06-23 WO PCT/GB2004/002705 patent/WO2005000310A1/en not_active Ceased
- 2004-06-23 AU AU2004251481A patent/AU2004251481B2/en not_active Ceased
- 2004-06-23 JP JP2006516468A patent/JP5348841B2/ja not_active Expired - Fee Related
- 2004-06-23 ES ES07013702.1T patent/ES2490598T3/es not_active Expired - Lifetime
- 2004-06-23 NZ NZ544181A patent/NZ544181A/en not_active IP Right Cessation
- 2004-06-23 PT PT70137021T patent/PT1889621E/pt unknown
- 2004-06-23 DK DK04743056.6T patent/DK1644002T3/da active
- 2004-06-23 KR KR1020057024940A patent/KR101116518B1/ko not_active Expired - Fee Related
- 2004-06-23 HR HR20100127T patent/HRP20100127T1/hr unknown
- 2004-06-23 EA EA200600111A patent/EA013424B1/ru not_active IP Right Cessation
- 2004-06-24 PE PE2004000617A patent/PE20050286A1/es not_active Application Discontinuation
- 2004-06-25 MY MYPI20042516A patent/MY176831A/en unknown
- 2004-06-25 AR ARP040102264A patent/AR044935A1/es not_active Application Discontinuation
-
2005
- 2005-12-21 IL IL172730A patent/IL172730A/en active IP Right Grant
-
2006
- 2006-01-27 NO NO20060443A patent/NO20060443L/no not_active IP Right Cessation
-
2010
- 2010-03-19 CY CY20101100259T patent/CY1109917T1/el unknown
-
2013
- 2013-05-08 JP JP2013098685A patent/JP5960089B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-04 HR HRP20140635TT patent/HRP20140635T1/hr unknown
- 2014-07-31 CY CY20141100577T patent/CY1115415T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050286A1 (es) | Formulacion de multiparticulas que comprenden oxicodona | |
| KR950702409A (ko) | 방출 조절 모르핀 제제(controlled release morphine preparation) | |
| LU92433I2 (fr) | Olodatérol, ses isomères optiques individuels, mélanges d'énantiomères individuels ou de racémates, ses sels d'addition d'acide avec des acides pharmaceutiquement acceptables, ainsi que ses solvates et/ou ses hydrates, en particulier l'olodatérol et le chlorhydrate d'olodatérol | |
| ES2572980T3 (es) | Combinación de inhibidores de la proteasa del VHC con un tensioactivo | |
| EP1730163A4 (en) | Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid | |
| LU92595I2 (fr) | Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium | |
| NO20073461L (no) | Matrikstypepreparater for vedvarende frigjoring som inneholder basiske medikamenter eller salter derav, samt fremgangsmate for fremstilling derav | |
| ATE84706T1 (de) | Spheroiden. | |
| BRPI0517916B8 (pt) | comprimido compreendendo carbonato de sevelamer e cloreto de sódio, e, uso de um comprimido | |
| WO2004108067A3 (en) | Programmed drug delivery system | |
| EA201792224A1 (ru) | Композиции, содержащие ибрутиниб | |
| BRPI0608853B8 (pt) | composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes | |
| CU23367A3 (es) | Formulación de moxifloxacino con sal común | |
| BRPI0415014A (pt) | formulações em multipartìculas de pantoprazol, cápsula e embalagem que as compreendem, método de produção das formulações, uso e composição | |
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| EP1885380A4 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ARSENE (III ACID), SODIUM SALT AND THEIR DERIVATIVES FOR THE TREATMENT OF UROGENITAL CANCER AND METASTASES THEREOF | |
| BRPI0416938A (pt) | agente de formação de imagem, composição, conjugado, kit para a preparação da composição radiofarmacêutica | |
| NO20042011L (no) | Fremgangsmate ved fremstilling av en farmasoytisk sammensetning omfattende 5-aminosalisylsyre for bruk ved behandling av ulcerativ kolitt og Crohns sykdom | |
| Ihalainen et al. | Comparison of phencyclidine-induced spatial learning and memory deficits and reversal by sertindole and risperidone between Lister Hooded and Wistar rats | |
| ATE401060T1 (de) | Schnell zerfallende tablette | |
| PE20130180A1 (es) | Soluciones farmaceuticas orales que comprenden telbivudina | |
| BRPI0517245A (pt) | suspensão farmacêutica e de acetaminofeno isentas de corantes | |
| NZ591213A (en) | A formulation of canfosfamide consisting of 50 mg/mL canfosfamide hydrochloride in aqueous sodium citrate buffer | |
| EP1968606A4 (en) | PREPARATION OF PHARMACEUTICAL SALTS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC ACID | |
| BR0307319A (pt) | Forma de dosagem oral para liberação controlada de droga |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |